BIAFINE Topical Emulsion is used for the dressing and management of wounds, pressure sores, leg ulcers, 1st and 2nd degree burns including sunburns, donor and graft sites, skin reactions to radiation therapy, and minor scrapes.
Important Safety Information
BIAFINE should not be used on any wound until directed by a healthcare professional. Do not use BIAFINE on bleeding wounds, skin rashes related to food or medication allergies, or when an allergy to one of the ingredients is known.
Do not apply BIAFINE within 4 hours of a radiation session and do not miss an application during the course of radiation therapy, even for one day.
Do not apply BIAFINE to a skin graft until your healthcare professional has instructed you to do so.
BIAFINE is for topical use only. If swallowed, contact a healthcare professional or Poison Control Center immediately. Keep out of reach of children.
BIAFINE should not be used prior to extended exposure to the sun.
Following application of BIAFINE a temporary tingling sensation may occur (10 to 15 minutes).
If a wound has become infected, your healthcare professional will advise you whether to continue the use of BIAFINE while being treated with an anti-infective.
If your condition doesn’t improve within 10-14 days, see your healthcare professional.
See Instructions for Use for detailed directions for the proper use of BIAFINE on various types of wounds and burns. See your healthcare professional if you have any questions or concerns.
Not available in select states including MA, MT, NH, NY, and TX, due to state regulations regarding the ability of physicians to dispense prescription drug products in their offices.
References: 1. BIAFINE topical emulsion [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals; 2012. 2. Coulomb B, Friteau L, Dubertret L. Biaﬁne applied on human epidermal wounds is chemotactic for macrophages and increases the IL-1/IL-6 ratio. Skin Pharmacol. 1997;10(5-6):281-287. 3. Boisnic S, Branchet-Gumila M-C, Nizri D, Ben Slama L. Histochemical and biochemical modiﬁcations induced by experimental irradiation of human skin maintained in survival conditions and modulation by application of an emulsion containing trolamine. Int J Tissue React. 2003;25(1):9-18. 4. Dr. Rendon Investigator Initiated Study. June 25, 2007. Data on ﬁle. Valeant Pharmaceuticals.